Kala Pharmaceuticals, Inc. (KALA)

Kala Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	19	19	58	79	380	127
Market Cap Growth	-26.36%	-67.46%	-26.91%	-79.15%	198.27%	-22.87%
Enterprise Value	7	4	30	65	328	143
PE Ratio	-	-0.45	-1.29	-0.56	-3.64	-1.35
PS Ratio	-	-	14.88	7.05	59.76	20.99
PB Ratio	2.86	2.51	3.05	4.72	3.80	4.29
P/FCF Ratio	-0.76	-0.66	-0.73	-0.73	-4.10	-1.36
P/OCF Ratio	-0.77	-0.68	-0.73	-0.73	-4.19	-1.37
EV/Sales Ratio	-	-	7.81	5.81	51.49	23.58
EV/EBITDA Ratio	-0.32	-0.12	-0.83	-0.49	-3.53	-1.72
EV/EBIT Ratio	-0.31	-0.12	-0.81	-0.49	-3.42	-1.67
EV/FCF Ratio	-0.36	-0.15	-0.38	-0.60	-3.54	-1.52
Debt / Equity Ratio	5.49	4.84	2.26	4.77	1.01	3.41
Debt / EBITDA Ratio	-1.10	-1.01	-1.17	-0.61	-1.09	-1.22
Debt / FCF Ratio	-1.24	-1.27	-0.54	-0.74	-1.09	-1.08
Quick Ratio	4.08	6.10	2.74	2.93	7.34	3.92
Current Ratio	4.22	6.34	3.35	3.32	7.71	4.26
Asset Turnover	0	0	0.04	0.06	0.03	0.04
Interest Coverage	-5.83	-6.26	-5.17	-16.02	-11.15	-10.13
Return on Equity (ROE)	-368.90%	-282.80%	952.00%	-209.50%	-87.60%	-174.60%
Return on Assets (ROA)	-66.90%	-66.00%	-48.60%	-73.30%	-43.90%	-54.60%
Return on Capital (ROIC)	-94.53%	-88.81%	-132.41%	-134.28%	-47.90%	-67.41%
Earnings Yield	-207.73%	-223.85%	-77.38%	-179.93%	-27.44%	-74.02%
FCF Yield	-155.23%	-151.13%	-136.56%	-137.57%	-24.37%	-73.79%
Buyback Yield / Dilution	-35.96%	-59.94%	-15.50%	-25.67%	-53.11%	-27.87%
Total Shareholder Return	-35.96%	-59.94%	-15.50%	-25.67%	-53.11%	-27.87%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).